FDA Determines Regulatory Review Period for TAVALISSE Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of TAVALISSE, a human drug product, following a submission to the US Patent and Trademark Office (USPTO). This determination is a requirement by law and has been published as a notice by the FDA.